Skip to main content

Disclaimer

You agree to use of this website at your own risk. The information provided on this website is meant to be used by professionals. Due to the changing nature of laws and regulations and the inherent hazards of electronic communication, there may be delays, omissions or inconsistencies in the information provided on this website.

Although the composition and maintenance of the information provided on this website is done with the utmost care, Fagron cannot guarantee that this information is always fully accurate, complete and current. Fagron, the leadership of the company, its employees, nor any third party listed on this website bear any responsibility or liability whatsoever for any direct or indirect loss arising from using, relying or acting in response to the information provided on this website, except on the part of Fagron where there is intent or gross negligence.

Certain statements on this website are forward-looking statements. Such statements include, but are not limited to, statements about strategic options, future strategies and expected results of those strategies. These statements are based on current internal estimates and expectations of Fagron as well as market expectations, and are valid on the date they are made. Fagron's actual results could differ from those in forward-looking statements. Fagron declares it’s not bound to follow the evolution of these risks. Any uncertainties or revisions made to the forward-looking statements on this website, including corrections due to future events and developments, will not be reflected.

Third party websites whose links can be found on this website, will not be under the control of Arseus, nor created or maintained. Fagron, the management of the company and its employees bear no responsibility or liability regarding the content of these third party sites, and whether these third party sites comply or not with applicable laws and regulations. As a result, Fagron, the leadership of the company and its employees bear no responsibility or liability whatsoever for any direct or indirect damages resulting from use of, or reliance on the actions taken based on this third party website information. The provisions of this "Legal disclaimer" may be changed without prior notice.

 

Formulation Disclaimer

While a great deal of effort has been spent to ensure the accuracy of the formulations contained herein, no claims are made as to the uses, safety, efficacy or bioavailability of these recommendations. This information is not intended to be patient education and should not be used as a substitute for professional diagnosis and treatment. The content of this brochure cannot be construed as (medical) advice, recommendation or opinion. Medical professionals, doctors and compounding pharmacists using this information are advised to do so solely if appropriate in their own professional opinion and judgement. The efficacy of any formulation is directly related to its preparation / selection of the compounding facility while the compounded medicine does not constitute a final registered medication; thus Fagron does not accept and cannot be held responsible or liable in any case for the formulations or information contained herein and for any patent infringement. 

 

SyrSpend® SF stability disclaimer

The compatibility studies demonstrate the wide application of SyrSpend® SFSF for compounding. The purchasers will determine the suitability, safety and effectiveness of their applications. Fagron's database helps the health scientists in exploring possible applications. The absence of an API from the compatibility list does not mean that the material cannot be mixed with SyrSpend® SF. In case that you use SyrSpend® SF in combination with an API or a crushed tablet which is not listed in the compatibility table, the compounded product could still form an elegant, tasteful and physically stable product which improves patient's compliance. In that case it is recommended that the pharmacist should assign a short expiry date based on internal protocols, risk analysis or guidelines from accredited pharmacopoeias.